Canine distemper
Reading File
Now let me search the medical library and web in parallel.
Finding Sources
Searching the Web
canine distemper virus pathogenesis clinical signs treatment 2024
Searching PubMed
"canine distemper"[MeSH Terms] AND treatment
Finding Sources
Reading Web Page
https://www.merckvetmanual.com/infectious-diseases/canine-di…
The medical library is human-medicine focused and only references canine distemper tangentially (in the context of paramyxovirus, Paget's disease, etc.). The Merck Veterinary Manual extraction plus web data gives a strong foundation. Let me get more detail from the comprehensive 2026 review and the ASPCA treatment PDF.
Reading Web Page
https://www.veterinarypaper.com/pdf/2026/vol11issue1S/PartC/…
Finding Sources
I now have sufficient information for a comprehensive answer. Here it is:
Canine Distemper
Overview
Canine distemper (CD) is a highly contagious, often fatal systemic viral disease of domestic dogs and a wide range of wildlife species. The causative agent is Canine Distemper Virus (CDV), formally classified as Canine morbillivirus, a single-stranded negative-sense RNA virus in the family Paramyxoviridae, genus Morbillivirus - closely related to human measles virus and cattle rinderpest virus.
Etiology and Pathogenesis
Virus entry and spread:
CDV enters primarily via aerosol or contact with respiratory secretions. It first replicates in lymphoid tissue of the upper respiratory tract, producing an early viremia. Systemic dissemination follows via:
- SLAM (CD150) receptors on lymphocytes, monocytes, and macrophages - driving immune cell spread
- Nectin-4 receptors on epithelial cells - enabling virus shedding from mucosal surfaces
Immunosuppression is a hallmark of CDV infection - the virus depletes lymphoid tissue (lymphopenia is a key early finding) and antagonizes Type I interferon signalling, leaving the host severely immunocompromised and predisposed to secondary bacterial infections.
CNS involvement: CDV crosses the blood-brain barrier via infected immune cells. Neurologic disease results from both direct viral cytopathic effect and immune-mediated chronic progressive demyelination, which can continue even after the peripheral virus is cleared.
Epidemiology
- Host range: Broad - domestic dogs, wolves, foxes, ferrets, mink, raccoons, large felids (lions, tigers), sea otters, and other carnivores. CDV is a significant threat to endangered wildlife species.
- Transmission: Direct contact, aerosol droplets, fomites. Infected dogs shed virus before clinical signs appear and can continue shedding for weeks.
- Most at risk: Unvaccinated or incompletely vaccinated young dogs (puppies 3-6 months, when maternal antibodies wane).
Clinical Signs
CDV produces a characteristic diphasic fever and multisystemic disease:
Phase 1 (Days 3-6 post-infection)
- Transient fever (often unnoticed)
- Leukopenia - notably lymphopenia
- Anorexia, lethargy
Phase 2 (after a brief afebrile interval)
| System | Signs |
|---|---|
| Respiratory | Serous-to-mucopurulent nasal discharge, cough, pneumonia |
| Ocular | Serous-to-mucopurulent ocular discharge, keratoconjunctivitis |
| Gastrointestinal | Vomiting, diarrhea, anorexia |
| Dermatologic | Pustular dermatitis (rare); hyperkeratosis of footpads and nasal planum ("hard pad disease") |
| Neurologic | Myoclonus (rhythmic muscle twitching - often a persistent sign), ataxia, focal or generalized seizures, circling, behavioral changes |
Key point: Neurologic signs may appear concurrent with systemic signs, follow them by days-to-weeks, or arise months later as a result of chronic demyelination - even after apparent clinical recovery.
Diagnosis
Clinical suspicion is the starting point, especially in young, unvaccinated dogs with multisystemic signs. Laboratory confirmation is essential because signs overlap with parvovirus, adenovirus, influenza, and rabies.
Sample selection by disease phase:
- Early viremia: whole blood / buffy coat
- Respiratory phase: conjunctival and nasal swabs
- Mid-to-late infection: urine
- Neurologic phase: cerebrospinal fluid (CSF)
Diagnostic methods:
- RT-PCR / qRT-PCR - gold standard for direct virus detection; highly sensitive and specific
- Immunofluorescence assay (IFA) - antigen detection in cells from conjunctiva, nasal mucosa, blood smears
- ELISA - serology for antibody detection (less useful in early disease or vaccinated dogs)
- Histopathology - eosinophilic intranuclear and intracytoplasmic inclusion bodies in epithelial cells
- Whole-genome sequencing - increasingly used for epidemiologic and phylogenetic surveillance
- MRI - for CNS involvement; shows demyelinating lesions
Treatment
There is no specific antiviral approved for CDV treatment. Management is entirely supportive and symptomatic:
| Problem | Intervention |
|---|---|
| Dehydration | IV or SC fluid therapy |
| Secondary bacterial pneumonia | Broad-spectrum antibiotics (amoxicillin-clavulanate, doxycycline) |
| Seizures | Phenobarbital, diazepam (for acute), levetiracetam |
| Myoclonus | Methocarbamol (partial benefit only) |
| Nutritional support | Assisted feeding if anorexic |
| Ocular discharge / corneal damage | Topical ophthalmic antibiotics |
Experimental / investigational approaches currently under study:
- Passive immunotherapy (hyperimmune serum or CDV-specific antibodies)
- Antiviral compounds (ribavirin, novel small molecule inhibitors)
- mRNA-based vaccine platforms for prevention
Prognosis:
- Dogs with only respiratory and GI signs - good prognosis; most recover fully with supportive care
- Dogs with neurologic signs - guarded to poor; prognosis worsens with severity and progression of CNS involvement
- Survivors may have permanent sequelae: persistent myoclonus, ataxia, cognitive deficits, seizure disorders
Prevention
Vaccination
Vaccination is the cornerstone of prevention and is highly effective:
- Modified live virus (MLV) vaccines: most widely used; typically combined as CDV-CPV-CAV (DHPPi) polyvalent vaccine
- Recombinant canarypox-vectored vaccines: safe for immunocompromised animals and young puppies; not blocked by maternal antibodies to the same degree as MLV
- mRNA-based vaccines: emerging platform under development
Core vaccination schedule (standard):
- Puppies: series starting at 6-8 weeks, every 2-4 weeks until ≥16 weeks of age (to overcome maternal antibody interference)
- Adults: booster 1 year after puppy series, then every 3 years per WSAVA guidelines
Challenge: Maternal antibodies can neutralize vaccine virus in puppies aged 6-12 weeks, creating a "window of susceptibility" - a key reason puppy series are repeated.
Biosecurity
- Isolate confirmed or suspected CDV cases immediately
- Disinfect with bleach (1:32 dilution), quaternary ammonium compounds, or formaldehyde - CDV is susceptible to most common disinfectants
- Recovered dogs may shed virus for weeks - alert adopters/owners
Connection to Human Medicine
While CDV does not infect humans, it has relevance in human medicine:
- The CDV nucleocapsid protein is implicated as a possible environmental trigger for Paget's disease of bone - viral particles resembling paramyxoviruses are found in pagetic osteoclasts (alongside measles and RSV antigens)
- CDV has been proposed as one of several viral antigens that may trigger autoimmune demyelinating disease (e.g., MS-like conditions in experimental models)
- CDV is a One Health concern given its ability to cause large-scale outbreaks in endangered carnivores (African lions, Amur tigers, black-footed ferrets)
Key Points Summary
- CDV is a Morbillivirus spread by aerosol; causes lymphopenia and profound immunosuppression
- Classic presentation: diphasic fever + respiratory + GI signs +/- neurologic signs (including the hallmark myoclonus)
- "Hard pad" (hyperkeratosis of nasal planum/footpads) is a classic, though not invariable, physical finding
- Diagnosis by RT-PCR from swabs, blood, or urine depending on stage
- No specific antiviral - supportive care is the mainstay
- Vaccination is effective and is a core canine vaccine; schedule completion in puppies is critical to close the maternal antibody window
- Neurologic involvement carries guarded-to-poor prognosis with potential for permanent sequelae
Sources: Merck Veterinary Manual - Canine Distemper (updated June 2026); ASPCA Pro CDV Treatment Recommendations; Rivera-Martinez et al. comprehensive CDV review, Int J Vet Sci Animal Husbandry 2026.
Dose rate of meloxicam for dog
Meloxicam in dogs is typically dosed at 0.2 mg/kg on day 1 (loading dose), then 0.1 mg/kg once daily for maintenance, given orally or by injection.
Searching sources...
Finding Sources
Searching the Web
meloxicam dose rate dogs mg/kg veterinary 2024
This is a shared conversation. Sign in to Orris to start your own chat.